Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/6659
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAtkins, G.-
dc.contributor.authorBouralexis, S.-
dc.contributor.authorEvdokiou, A.-
dc.contributor.authorHay, S.-
dc.contributor.authorLabrinidis, A.-
dc.contributor.authorZannettino, A.-
dc.contributor.authorHaynes, D.-
dc.contributor.authorFindlay, D.-
dc.date.issued2002-
dc.identifier.citationBone, 2002; 31(4):448-456-
dc.identifier.issn8756-3282-
dc.identifier.issn1873-2763-
dc.identifier.urihttp://hdl.handle.net/2440/6659-
dc.descriptionCopyright © 2002 Elsevier Science Inc. All rights reserved.-
dc.description.abstractApo2 ligand (Apo2L/TRAIL) is a member of the tumor necrosis factor (TNF) cytokine family. Apo2L/TRAIL can selectively induce programmed cell death in transformed cells, although its wide tissue distribution suggests potential physiological roles. We have investigated the expression, in human osteoblast-like cells (NHBC), of Apo2L/TRAIL and the known Apo2L/TRAIL death receptors, DR4 and DR5, and the Apo2L/TRAIL decoy receptors, DcR-1, DcR-2, and osteoprotegerin (OPG). NHBC expressed abundant mRNA corresponding to each of these molecular species. Immunofluorescence staining demonstrated that Apo2L/TRAIL protein was abundant within the cytoplasm of NHBC and OPG was strongly expressed at the cell surface. DR5 and DcR-2 were present in the cell membrane and cytoplasm and DcR-1 was confined to the nucleus. DR4 staining was weak. Neither Apo2L/TRAIL alone, nor in combination with chemotherapeutic agents of clinical relevance to treatment of osteogenic sarcoma, induced cell death in NHBC, as assessed morphologically and by activation of caspase-3. In contrast, the human osteogenic sarcoma cell lines, BTK-143 and G-292, were sensitive to exogenous Apo2L/TRAIL alone, and to the combined effect of Apo2L/TRAIL/cisplatin and Apo2L/TRAIL/doxorubicin treatments, respectively. In NHBC, we observed strong associations between the levels of mRNA corresponding to the pro-apoptotic molecules, Apo2L/TRAIL, DR4, and DR5, and those corresponding to pro-survival molecules, DcR-1, DcR-2, OPG, and FLIP, suggesting that the balance between pro-survival and pro-apoptotic molecules is a mechanism by which NHBC can resist Apo2L/TRAIL-mediated apoptosis. In contrast, osteogenic sarcoma cells had low or absent levels of DcR-1 and DcR-2. These results provide a foundation to explore the role of Apo2L/TRAIL in osteoblast physiology. In addition, they predict that therapeutic use of recombinant Apo2L/TRAIL, in combination with chemotherapeutic agents to treat skeletal malignancies, would have limited toxic effects on normal osteoblastic cells.-
dc.description.statementofresponsibilityG. J. Atkins, S. Bouralexis, A. Evdokiou, S. Hay, A. Labrinidis, A. C. W. Zannettino, D. R. Haynes and D. M. Findlay-
dc.description.urihttp://www.elsevier.com/wps/find/journaldescription.cws_home/525233/description#description-
dc.language.isoen-
dc.publisherElsevier Science Inc-
dc.source.urihttp://dx.doi.org/10.1016/s8756-3282(02)00858-x-
dc.subjectHuman osteoblasts-
dc.subjectApo2L/TRAIL-
dc.subjectReceptors-
dc.subjectApoptosis-
dc.subjectCaspase-
dc.subjectChemotherapy-
dc.titleHuman osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis-
dc.typeJournal article-
dc.identifier.doi10.1016/S8756-3282(02)00858-X-
pubs.publication-statusPublished-
dc.identifier.orcidAtkins, G. [0000-0002-3123-9861]-
dc.identifier.orcidEvdokiou, A. [0000-0001-8321-9806]-
dc.identifier.orcidZannettino, A. [0000-0002-6646-6167]-
Appears in Collections:Aurora harvest 5
Orthopaedics and Trauma publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.